Category Archives: Investment

Winners outpace losers in wild week for healthcare stocks; my picks and pans.

Leading the largest pack of winners in quite a while, XOMA Corp. (Nasdaq:XOMA) soared $5.64, or 48% over the week, to $11.10, after the company revealed an agreement to out-license… Read more »

Alexion on a roll as Soliris gets label expansion in EU; although flying under the radar, analysts, investors still bullish.

The News: Alexion Pharmaceuticals Inc. (New Haven CT) got another shot in the arm this week with the EU approving its key revenue driver Soliris for an additional indication. EU approval… Read more »

Endo coming out of the darkness into the light; contrarians, buy this name.

The News: Endo International Plc (Dublin IRL) on Tuesday (August 8, 2017) lowered its full-year revenue forecast, saying it expected lower sales of branded drugs to add to the pricing… Read more »

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »

Biogen’s poster presentation for Alzheimer’s candidate hardly noticed at London AAIC meeting as market focuses on quarterly results instead; start accumulating.

Biogen Inc. (Cambridge MA) laid out long-term plans to strengthen its core multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results,… Read more »

IPO breakout starts summer off with a bang; but two new issues fizzle.

It was certainly an off week (June 26 to 30, 2017) to for healthcare stocks, with the Nasdaq Healthcare Index (IXHC) giving back 2% to 732.05 after hitting an all-time… Read more »

Moleculin Biotech soars on research deal for novel cancer med; Buy signals abound, but not for the risk-averse.

The News: Moleculin Biotech Inc. (Houston TX) is one of the biggest, and quietest, gainers on the Nasdaq earlier in the week, soaring $1.92, or 275% on the week, to… Read more »

Idorsia leaps 45% in market debut; Actelion spinoff looks like sure bet with J&J backing to boot. How to invest.

Idorsia Ltd. (Allschwil CHE), the research-based spin-out from Actelion following the latter’s $30 billion acquisition by Johnson & Johnson (New Brunswick NJ), which has now been completed, started trading on… Read more »

GlycoMimetics gets Breakthrough title; stock explodes but what’s next?

The News: GlycoMimetics Inc. (Rockville MD) soared Thursday (May 18, 2017), up 99% to $10.67. The unforeseen blastoff followed Tuesday (May 16, 2017) night’s announcement that the company’s clinical-stage acute… Read more »

Akebia surges on anemia drug deal; is a much bigger breakout looming?

The News: Akebia Therapeutics Inc. (Cambridge MA) leaped 18% Tuesday (May 16, 2017) sparked by news the fledgling dialysis treatment developer and Swiss backer Vifor Pharma Group Ltd. (Glattburg) agreed… Read more »